Impact of Infections in Patients with Acute Myeloid Leukemia Receiving Cytarabine+ Daunorubicin (7+3) Versus Azacitidine and Venetoclax during Induction Chemotherapy. Indus Journal of Bioscience Research, [S. l.], v. 3, n. 1, p. 190–196, 2025. DOI: 10.70749/ijbr.v3i1.469. Disponível em: https://ijbr.com.pk/IJBR/article/view/469. Acesso em: 14 aug. 2025.